Skip to Content

'
Rena V. Sellin, M.D., F.A.C.P., F.A.C.E.

Present Title & Affiliation

Primary Appointment

Clinical Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Research interests  include endocrine neoplasms and clinical outcomes of therapies. 

Clinical Interests

Clinical interests include thyroid cancer, skeletal health, endocrine neoplasms, and endocrine sequelae of cancer therapies.  

For physician to physician referrals, please call our main office line at (713) 792-2841.

For new patient self referrals, please contact our new patient referral coordinators at: 
(713) 563-4400 - telephone
(713) 563-4611 - fax

or visit us at https://my.mdanderson.org/

For new international patients, please complete the International Center form or contact the International Center at 001-713-745-0450.  

For established patients, please contact your primary patient care center at:  
Endocrine Center:                (713) 563-7600    (center information can be reviewed here:  Endocrine Center)
Internal Medicine Center:    (713) 792-2340

 For general department information, please select the link below.

Department of Endocrine Neoplasia and Hormonal Disorders

 

Education & Training

Degree-Granting Education

1974 Albert Einstein College of Medicine, New York, NY, MD, Medicine
1971 Barnard College, New York, NY, BA, Biology

Postgraduate Training

7/1979-6/1980 Research Fellowship, Endocrinology and Metabolism, Northwestern University Medical School, Chicago, IL, Lawrence Phillips, MD
7/1977-6/1979 Clinical Fellowship, Endocrinology and Metabolism, Northwestern University Medical School, Chicago, IL, Lawrence Phillips, MD
7/1974-6/1977 Clinical Residency, Montefiore Hospital and Medical Center, Bronx, New York City, NY

Board Certifications

1981 American Board of Internal Medicine, Endocrinology
1977 American Board of Internal Medicine

Experience/Service

Endowed Positions

Emeritus, Naguib A. Samaan, Houston, TX, 2007-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Fareau GG, Lopez A, Stava C, Vassilopoulou-Sellin R. Systemic chemotherapy for adrenocortical carcinoma: Comparative responses to conventional first-line therapies. Anticancer Drugs 19(6):637-44, 7/2008. PMID: 18525324.
2. Fosså SD, Vassilopoulou-Sellin R, Dahl AA. Long-Term physical sequelae after adult onset cancer. J Cancer Surviv 2(1):3-11, 3/2008. e-Pub 12/4/2007. PMID: 18648982.
3. Vecil GG, Papadopoulos NV, Vassilopoulou-Sellin R, McCutcheon IE. Interferon-induced hypothyroidism causing reversible pituitary enlargement. Endocr Pract 14(2):219-223, 2008. PMID: 18308662.
4. Nunez R, Vassilopoulou-Sellin R, Fareau GG, Drucker CR. Urticarial-like skin rash as an allergic manifestation to 123-I and 131-I sodium iodine capsules. Thyroid 17(3):277-278, 2007.
5. Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, DeGracia B, Willey JS, Bruera E. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107(12):2949-57, 12/2006. PMID: 17103445.
6. Carmack Taylor CL, Demoor C, Smith MA, Dunn AL, Basen-Engquist K, Nielsen I, Pettaway C, Sellin R, Massey P, Gritz ER. Active for life after cancer: A randomized trial examining a lifestyle physical activity program for prostate cancer patients. Psychooncology 15(10):847-62, 10/2006. PMID: 16447306.
7. Stava CJ, Lopez A, Vassilopoulou-Sellin R. Health profiles of younger and older breast cancer survivors. Cancer 107(8):1752-9, 10/2006. PMID: 16967441.
8. Stava C, Weiss LT, Vassilopoulou-Sellin R. Health profiles of 814 very long-term breast cancer survivors. Clin Breast Cancer 7(3):228-36, 8/2006. PMID: 16942639.
9. Stava C, Beck M, Weiss LT, Lopez A, Vassilopoulou-Sellin R. Health profiles of 996 melanoma survivors: the M. D. Anderson experience. BMC Cancer 6:95, 4/2006. PMCID: PMC1526747.
10. Habra MA, Vassilopoulou-Sellin R. Contribution of routine chest x-ray in the long-term follow-up of patients with differentiated thyroid carcinoma. Thyroid 16(3):303-6, 3/2006. PMID: 16571094.
11. Habra MA, Jimenez C, Wallace M, Evans DB, Vassilopoulou-Sellin R. Insulinoma in a marathon runner illustrating the effects of exercise on insulin sensitivity and glucose homeostasis. The Endocrinologist 16:20-4, 2006.
12. Fareau GG, Vassilopoulou-Sellin R. Late disease recurrence in patients diagnosed with and treated for differnetiated thyroid carcinoma. The Endocrinologist 16:329-34, 2006.
13. Stava C, Beck M, Vassilopoulou-Sellin R. Cataracts among cancer survivors. Am J Clin Oncol 28(6):603-8, 12/2005. PMID: 16317272.
14. Gonzalez RJ, Shapiro S, Sarlis N, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE. Laproscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 138(6):1078-85; discussion 1085-6, 12/2005. PMID: 16360394.
15. Elliott DD, Sellin R, Egger JF, Medeiros LJ. Langerhans cell histiocytosis presenting as a thyroid gland mass. Ann Diagn Pathol 9(5):267-74, 10/2005. PMID: 16198954.
16. Jimenez C, Yang Y, Kim HW, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF. Primary hyperparathyroidism and osteosarcoma: examination of a large cohort identifies three cases of fibroblastic osteosarcoma. J Bone Miner Res 20(9):1562-8, 9/2005. e-Pub 5/2005. PMID: 16059628.
17. Stava C, Beck M, Schultz PN, Vassilopoulou-Sellin R. Hearing loss among cancer survivors. Oncol Rep 13(6):1193-9, 6/2005. PMID: 15870942.
18. Habra MA, Vassilopoulou-Sellin R. Cervical spine metastasis mimicking thyroid bed uptake in follicular thyroid carcinoma. Thyroid 15(3):298-9, 3/2005. PMID: 15785252.
19. Schultz PN, Beck ML, Klein MJ, Stava C, Vassilopoulou-Sellin R. Breast Cancer: Relationship Between Menopausal Symptoms, Physiologic Health Effects of Cancer Treatment and Physical Constraints on Quality of Life in Long-Term Survivors. J Clin Nurs 14:204-11, 2005.
20. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, Clayman GL, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. Head Neck 26(8):716-26, 8/2004. PMID: 15287039.
21. Jimenez C, Dang GT, Schultz PN, El-Naggar A, Shapiro S, Barnes EA, Evans DB, Vassilopoulou-Sellin R, Gagel RF, Cote GJ, Hoff AO. A novel point mutation of the RET protooncogene involving the second intracellular tyrosine kinase domain in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 89(7):3521-6, 7/2004. PMID: 15240641.
22. Clayman GL, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 100(5):900-5, 3/2004. PMID: 14983483.
23. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic Hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100(4):851-8, 2/2004. PMID: 14770444.
24. Schultz PN, Stava C, Beck ML, Vassilopoulou-Sellin R. Ethnic/racial influences on the physiologic health of cancer survivors. Cancer 100(1):156-64, 1/2004. PMID: 14692036.
25. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR. Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10(1 Pt 1):113-23, 1/2004. PMID: 14734459.
26. Schultz PN, Stava C, Beck ML, Vassilopoulou-Sellin R. Internet message board use by patients with cancer and their families. Clin J Oncol Nurs 7(6):663-7, Nov-Dec, 11/2003. PMID: 14705483.
27. Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head Neck 25(5):349-56, 5/2003. PMID: 12692870.
28. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles in 5836 long-term cancer survivors. Int J Cancer 104(4):488-95, 4/2003. PMID: 12584748.
29. Royal RE, Delpassand ES, Shapiro SE, Fritsche HA, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression. Surgery 132(6):968-74; discussion 974-5, 12/2002. PMID: 12490843.
30. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Smith TL, Theriault RL. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. Cancer 95(9):1817-26, 11/2002. PMID: 12404273.
31. Vassilopoulou-Sellin R, Klein MJ. Health care priorities for menopausal women with a history of breast cancer. South Med J 95(11):1269-75, 11/2002. PMID: 12539992.
32. Fernandes JK, Klein MJ, Ater JL, Kuttesch JF, Vassilopoulou-Sellin R. Triiodothyronine supplementation for hypothalamic obesity. Metabolism 51(11):1381-3, 11/2002. PMID: 12404183.
33. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. The Impact of Cancer Survivors in the workplace. American Association of Occupational Health Nurses 50:222-6, 2002.
34. Vassilopoulou-Sellin R, Theriault R, Klein MJ. Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer. Gynecol Oncol 65(1):89-93, 4/1997. PMID: 9103397.
35. Vassilopoulou-Sellin R, Delpassand ES. Follicular Thyroid Cancer: Clinical outcome and impact of radioiodine therapy in patients with distant metastases. Int J Oncol 8:969-76, 1996.
36. Haynie TP, Vassilopoulou-Sellin R. How safe for the patient is I- 131 therapy for differentiated thyroid carcinoma? J Nucl Med 36(1):27-8, 1/1995. PMID: 7799077.
37. Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 160(4):341-343, 10/1990. PMID: 2221231.
38. Vassilopoulou-Sellin R, Rey-Bear N, Oyedeji CO. Bilirubin as an inhibitor of cartilage metabolism: effect on avian chondrocyte proliferation in cell culture. J Bone Miner Res 5(7):769-74, 7/1990. PMID: 2396503.
39. Vassilopoulou-Sellin R, Foster P, Oyedeji CO. Bilirubin and heme as growth inhibitors of chicken embryos in ovo. Pediatr Res 27(6):617-21, 6/1990. PMID: 2356106.
40. Vassilopoulou-Sellin R, Oyedeji CO. Hematoporphyrin can inhibit the metabolism and growth of embryonic chicken cartilage in vitro. Metabolism 39(3):316-20, 3/1990. PMID: 2308521.
41. Venkatesh S, Vassilopoulou-Sellin R, Samaan NA. Somatostatin analogue: use in the treatment of vipoma with hypercalcemia. Am J Med 87(3):356-7, 9/1989. PMID: 2549791.
42. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA. Adrenal cortical carcinoma. Cancer 64(3):765-9, 8/1/1989. PMID: 2743269.
43. Vassilopoulou-Sellin R, Oyedeji CO, Samaan NA. Bilirubin inhibits cartilage metabolism and growth in vitro. Metabolism 38(8):759-62, 8/1989. PMID: 2474743.
44. Vassilopoulou-Sellin R, Thompson MM, Oyedeji CO, Samaan NA. Heme inhibits cartilage metabolism and growth in vitro. Metabolism 38(1):52-6, 1/1989. PMID: 2909829.
45. Vassilopoulou-Sellin R, Oyedeji CO, Foster PL, Thompson MM, Saman NA. Hemoglobin as a direct inhibitor of cartilage growth in vitro. Horm Metab Res 21(1):11-4, 1/1989. PMID: 2925149.
46. Vassilopoulou-Sellin R, Oyedeji CO. Heme overload inhibits the growth of normal rats. Growth Dev Aging 53(3):123-7, 1989. PMID: 2599742.
47. Samaan NA, Ouais S, Ordonez NG, Choksi UA, Vassilopoulou-Sellin R, Hickey RC. Multiple endocrine syndrome type 1: clinical, laboratory findings, and management in 5 families. Cancer 64:741-52, 1989.
48. Vassilopoulou-Sellin R, Oyedeji CO. Tetrapyrroles as inhibitors of normal cartilage metabolism: relative potency of different compounds. J Bone Miner Res 3(6):681-8, 12/1988. PMID: 2855192.
49. Assaad SN, Vassilopoulou-Sellin R, Samaan NA. Pseudohypoglycemia in chronic leukemia. Tex Med 84(7):36-7, 7/1988. PMID: 3166239.
50. Vassilopoulou-Sellin R, Foster PL, Oyedeji CO, Samaan NA. Cartilage sulfation inhibitor from rat liver: partial characterization of properties and biologic action. Metabolism 37(1):38-45, 1/1988. PMID: 2447468.
51. Samaan NA, Schultz PN, Yang KP, Vassilopoulou-Sellin R, Maor MH, Cangir A, Goepfert H. Endocrine complications after radiotherapy for tumors of the head and neck. J Lab Clin Med 109(3):364-72, 3/1987. PMID: 3819573.
52. Assaad SN, Carrasco CH, Vassilopoulou-Sellin R, Samaan NA. Glucagonoma syndrome. Rapid response following arterial embolization of glucagonoma metastatic to the liver. Am J Med 82(3):533-5, 3/1987. PMID: 3030099.
53. Vassilopoulou-Sellin R, Lock RL, Oyedeji CO, Samaan NA. Cartilage sulfation inhibitor from rat liver curtails growth of embryonic chicken cartilage in vitro. Metabolism 36(1):89-94, 1/1987. PMID: 3796300.
54. Samaan NA, Vassilopoulou-Sellin R, Schultz PN, Rivera ME, Held B. Nonsuppressible insulin-like activity and somatomedin C levels in normal pregnant women, in pregnant women with gestational diabetes, and in umbilical cord blood of mature and premature infants. Am J Obstet Gynecol 153(4):457-61, 10/1985. PMID: 4050920.
55. Vassilopoulou-Sellin R, Wallis CJ, Samaan NA. Hormonal evaluation in patients with osteosarcoma. J Surg Oncol 28(3):209-13, 3/1985. PMID: 3856084.
56. Vassilopoulou-Sellin R, Phillips LS, Oyedeji CO, Samaan NA. Metabolic regulation of somatomedin activity in rat liver. J Endocrinol 101(3):257-61, 6/1984. PMID: 6726105.
57. Vassilopoulou-Sellin R, Oyedeji CO, Samaan NA. Cartilage sulfation inhibitors (CSI) in serum and liver of growth hormone-deficient starved rats. Horm Metab Res 16(3):156, 3/1984. PMID: 6714928.
58. Vassilopoulou-Sellin R, Oyedeji CO, Samaan NA. Extraction of cartilage sulfation inhibitors and somatomedins from rat liver. Endocrinology 114(2):576-81, 2/1984. PMID: 6690293.
59. Phillips LS, Brodsky IG, Vassilopoulou-Sellin R, Scholz TD. Nutrition and somatomedin. X. Comparison of insulin-like activity of somatomedins extracted from liver and serum. Metabolism 33(1):34-41, 1984. PMID: 6419011.
60. Anderson BJ, Samaan NA, Vassilopoulou-Sellin R, Ordonez NG, Hickey RC. Parathyroid carcinoma: features and difficulties in diagnosis and management. Surgery 94(6):906-15, 12/1983. PMID: 6648803.
61. Vassilopoulou-Sellin R, Oyedeji CO, Samaan NA. Somatomedin inhibitors in serum and liver of growth hormone-deficient diabetic rats. Diabetes 32(3):262-4, 3/1983. PMID: 6825966.
62. Nader S, Hickey RC, Vassilopoulou-Sellin R, Samaan NA. Adrenal cortical carcinoma: a study of 77 cases. Cancer 52:707-711, 1983.
63. Kantarjian HM, Saad MT, Estey EH, Vassilopoulou-Sellin R, Samaan NA. Hypercalcemia in disseminated candidiasis. Amer J Med 74:721-724, 1983.
64. Vassilopoulou-Sellin R, Phillips LS. Extraction of somatomedin activity from rat liver. Endocrinology 110(2):582-9, 2/1982. PMID: 7056213.
65. Vassilopoulou-Sellin R, Phillips LS, Reichard LA. Nutrition and somatomedin. VII. Regulation of somatomedin activity by the perfused rat liver. Endocrinology 106(1):260-7, 1/1980. PMID: 7349957.
66. Phillips LS, Vassilopoulou-Sellin R, Reichard LA. Nutrition and somatomedin VIII. The "somatomedin inhibitor" in diabetic rat serum is a general inhibitor of growing cartilage. Diabetes 28(10):919-24, 10/1979. PMID: 478184.

Invited Articles

1. Fareau GG, Vassilopoulou-Sellin R. Menopausal health after breast cancer. Practical Guides to Multidisciplinary Care at M. D. Anderson Cancer Center: Monograph on Breast Cancer 21:639-657, 2007.
2. Vassilopoulou-Sellin R. Hormone Replacement Therapy after Breast Cancer. MDACC Breast Med Onc: Clin Issues, Therapeutic Advances 3:4-5, 2004.
3. Gagel, R, Vassilopoulou-Sellin R, Raney RB, Evans DB, Fornage BD, Goepfert H. Familial papillary thyroid cancer. M.D. Anderson Oncology 12:1-6, 1997.
4. Vassilopoulou-Sellin R. Current approaches for hypercalcemia. Cope 1:10-11, 1995.
5. Phillips LS, Vassilopoulou-Sellin R. Somatomedins (first of two parts). N Engl J Med 302(7):371-80, 2/1980. PMID: 6243390.
6. Phillips LS, Vassilopoulou-Sellin R. Somatomedins (second of two parts). N Engl J Med 302(8):438-46, 2/1980. PMID: 6986028.
7. Phillips LS, Vassilopoulou-Sellin R. Nutritional regulation of somatomedin. Am J Clin Nutr 32(5):1082-96, 5/1979. PMID: 373416.

Editorials

1. Vassilopoulou-Sellin R. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Breast Diseases: A Yearbook Quarterly, 2007.
2. Vassilopoulou-Sellin R. Gabapentin for hot flashes in 420 women with breast cancer: a randomized double-blind placebo-controlled trial. Breast Diseases: A Yearbook Quarterly 17:133, 2006.
3. Vassilopoulou-Sellin. Hypothyroidism may be related to breast cancer in postmenopausal women. Breast Disease: A Yearbook Quarterly, 2006.
4. Vassilopoulou-Sellin R. Use of Postmenopausal Hormone, Alcohol, and Risk for Invasive Breast Cancers. Breast Disease: A Yearbook Quarterly 14:2, 2003.
5. Vassilopoulou-Sellin R. A Pilot Trial of Paroxetine for the Treatment of Hot Flashes and Associated Symptoms in Women with Breast Cancer. Breast Diseases: A Yearbook Quarterly 23:337-45, 2002.
6. Vassilopoulou-Sellin R. Bone Mass and Breast Cancer Risk in Postmenopausal Women. Breast Disease: A Yearbook Quarterly 13:1, 2002.
7. Vassilopoulou-Sellin R. Saliva as a Medium for Investigating Intra- and Interindividual Differences in Sex Hormone Levels in Premenopausal Women. Breast Diseases: A Yearbook Quarterly 10:59-64, 2001.
8. Vassilopoulou-Sellin R. Bone Mass and The Risk of Breast Cancer Among Postmenopausal Women. Breast Diseases: A Yearbook Quarterly 8:206-7, 1997.
9. Vassilopoulou-Sellin R. Hormone replacement therapy in women with breast cancer: Do the risk outweigh the benefits? Breast Diseases: A Yearbook Quarterly 7:243, 1996.
10. Vassilopoulou-Sellin R. Hormone replacement treatment and breast cancer risk. Breast Diseases: A Yearbook Quarterly 7:32, 1996.

Abstracts

1. Fareau GG, Vassilopoulou-Sellin R. Chemotherapeutic management of adrenocortical carcinoma: The M. D. Anderson Cancer Center experience. American Society of Clinical Oncology, 2006.
2. Cabanillas M, Vassilopoulou-Sellin R, Thomas D, Bruera E, Mattiuzzi G, Busaidy N, Hoff A, Waguespack S, Cassat J, Brandt M, Foudray M, Escalante C, Kantarjian H, Gagel R. Hypogonadismis common in adult male patients receiving frontline chemotherapy with Hyper-CVAD for acute lymphoblastic leukemia and lymphoblastic lymphoma (ALL/LL). Division of Internal Medicine Retreat, 2006.
3. Beck ML, Stava C, Vassilopoulou-Sellin R. Menopausal concerns of cancer survivors. 31st National Primary Care Nurse Practitioner Symposium, 2006.
4. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Relationship between quality of life and self-reported psychological problems in a large cohort of long-term cancer survivors. American Psychosocial Oncology Society Meeting, 2006.
5. Habra MA, Vassilopoulou-Sellin R. Cervical spine metastatsis mimicking the appearance of thyroid bed uptake in a patient with follicular thyroid carcinoma. American Thyroid Assn 76th Annual Meeting, 2004.
6. Habra MA, Jimenez C, Vassilopoulou-Sellin R. Cowden Syndrome Associated with Galactorrhea. American Association Clinical Endocrinology 13th Annual Meeting, 2004.
7. Stava C, Schultz PN, Beck ML, Vassilopoulou-Sellin R. Hearing loss in cancer survivors. MD Anderson, Internal Medicine & the Cancer Patient Conference, 2004.
8. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Cancer Survivorship: utilizing an internet message board as a research tool. American Society of Clinical Oncology 12th Annual Meeting, 2003.
9. Jimenez C, Busaidy N, Habra MA, Schultz PN, El-Naggar A, Clayman G, Diaz E, Evans D, Gagel RF, Garden A, Goepfert H, Hoff AO, Lee JE, Morrison WH, Rosenthal D, Sherman SI, Sturgis E, Waguespack SG, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 20 year experience. American Society of Clinical Oncology 12th Annual Meeting, 2003.
10. Jimenez C, Kim HW, Patel S, El-Naggar A, Vassilopoulou-Sellin R, Berry D, Gagel RF. The prevalence of hyperparathyroidism and Pagets Disease in Osteosarcoma: evidence supporting a relationship. American Association of Bone and Mineral Research, 2003.
11. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Smith TL, Theriault RL. Estrogen replacement therapy (ERT) for menopausal women with a history of breast cancer: results of a 5-year prospective study. The Endocrine Society's 84th Annual Meeting, 2002.
12. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health effects and quality of life in 5143 adult long-term cancer survivors. AM Soc Clin Oncool, 11th Annual Meeting, 2002.
13. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health effects and quality of life in long-term cancer survivors: a comparison among African, Asian, Hispanic, and White American survivors. ICC 8th Biennial Symposium on Minorities, the Medically Underserved and Cancer, 2002.
14. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health effects and quality of life in long-term cancer survivors: a comparison among African, Asian, Hispanic and White American survivors. National Cancer Institute, Cancer Survivorship: Resilience Across the Lifespan Meeting, 2002.
15. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 thyroid cancer survivors. National Cancer Institute, Cancer survivorship: resilience across the lifespan meeting, 2002.
16. Royal RE, Shapiro SE, Fritsche HA, Delpassand ES, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Improving the yield of preoperative parathyroid localization: Sestamibi imaging following thyroid suppression. American Association of Endocrine Surgeons Annual Meeting, 2002.
17. Kouvaraki M, Lee JE, Shapiro SE, Vassilopoulou-Sellin R, Sherman SI, Wirfel KL, Gagel RF, Evans DB. Pancreatic surgery in MEN1: early results with a standard oncologic approach. American Association of Endocrine Surgeons Annual Meeting, 2002.
18. Fernandes JK, Klein MJ, Jaffe N, Culbert SJ, Zietz H, Vassilopoulou-Sellin R. Skeletal health of childhood cancer survivors. 5th International Symposium of Clinical Advances in Osteoporosis, 2002.
19. Sekhar R, Vassilopoulou-Sellin R, Culbert S, Hoots WK, Klein MJ, Zietz H. Severe Osteopenia in a young boy with Kostman's Congenital Neutropenia treated with G-CSF: suggested therapeutic approach. AM Assoc Clin Endocrinol 10th Annual Meeting, 2001.
20. Vassilopoulou-Sellin R. Severe Osteopenia in Young Boy with Kostman's Congenital Neutropenia treated with G-CSF: suggested etiology and treatment. First combined International Bone and Mineral Society and European Calicified Tissue Research Meeting, Madrid Spain, 2001.
21. Vassilopoulou-Sellin R, Klein MJ. Triiodonine (T3) Supplementation can help patients with hypothalamic obesity lose weight. American Thyroid Association 74th Annual Meeting, 2001.

Book Chapters

1. Fareau GG, Vassilopoulou-Sellin R,. Menopausal Health, after Breast Cancer. In: M.D. Anderson Cancer Care Series: Breast Cancer, Second Edition, Ch 18, 505-524, 2007.
2. Schultz PN, Vassilopoulou-Sellin R. Adult Long Term Follow-up. In: The MD Anderson Manual Medical Oncology, Chapter 43. McGraw Hill, 1097-1106, 2006.
3. Habra MA, Busaidy NL, Vassilopoulou-Sellin R. Endocrine Malignancies. In: Medical Oncology: A Comprehensive Review, 3rd, 819-54, 2006.
4. Busaidy NL, Habra MA, Vassilopoulou-Sellin R. Endocrine Malignancies. In: The MD Anderson Manual of Medical Oncology, Chapter 31. McGraw, 819-854, 2006.
5. Habra MA, Busaidy NL, Vassilopoulou-Sellin R, Yeung SEJ. Endocrine Manifestations of Nonendocrine Tumors. In: Medical Oncology: A Comprehensive Review, 3rd, 993-1010, 2006.
6. Habra MA, Vassilopoulou-Sellin R, Clayman GL. Surgical Treatment and management of parathyroid cancer. In: Advanced Therapy in Surgical Oncology. Ed(s) Perrier ND. Decker Inc, in press, 2006.
7. Vassilopoulou-Sellin R, Lamont JP. Thyroid and Parathyroid Cancer. In: Cancer Management: A Multidisciplinary Appeal, 9th, Chapter 5, 91-110, 2006.
8. Fareau G, Vassilopoulou-Sellin R, Lustig R, Lamont J. Thyroid and parathyroid cancer. In: Cancer Management: A Multidisciplinary Approach, 9th, in press, 2006.
9. Meistrich ML, Vassilopoulou_Sellin R, Lipshultz LI. Adverse effects treatment: Gonadal dysfunction. In: Cancer: Principles and Practice of Oncology, 7th. Ed(s) DeVita VT, Hellman S, Roseberg SA. Lippincot Raven Press: Philadelphia, 2560-72, 2005.
10. Vassilopoulou-Sellin R. Differentiated Thyroid Cancer. In: Pediatric Oncology: M.D. Anderson Cancer Care Series. 5, 155-166, 2005.
11. Vassilopoulou-Sellin R. Brain Metastases from Thyroid Carcinoma and other Endocrine Malignancies. In: Intracranial Metastases. Ed(s) Raymond Sawaya. Blackwell Publishing Inc: Massachutes, 381-391, 2004.
12. Vassilopoulou-Sellin R. Management of Menopausal Symptoms. In: Advanced Therapy of Breast & Diseases, 2nd. C.B. Decker Inc, 799-805, 2004.
13. Wasan SM, Sellin JH, Vassilopoulou-Sellin R. The gastrointestinal tract and liver in Hypothyroidism. In: Werner and Ingbar’s The Thyroid. A Fundamental and Clinical Text, 9th. Ed(s) Ingbar SH and Braverman LE. J.B. Lippincott Co: Philadelphia, 796-802, 2004.
14. Wasan SM, Sellin JH, Vassilopoulou-Sellin R. The gastrointestinal tract and liver in Thyrotoxicosis. In: Werner and Ingbar's The Thyroid. A Fundamental and Clinical Text, 9th. Ed(s) Ingbar SH and Braverman LE. J. B. Lippencott Co: Philadelphia, 589-94, 2004.
15. Vassilopoulou-Sellin, R, Lustig R, Lamont JP. Thyroid & Parathyroid Cancer. In: Cancer Management : A Multidisciplinary Approach, 8th. PRR, Inc: Huntington, New York, 87-104, 2004.
16. McCarty T, Vassilopoulou-Sellin R, Lustig R. Thyroid & Parathyroid Cancer. In: Cancer Management: A Multidisciplinary Approach, 7th. Ed(s) Pazdur R, Coia L, Wagman L. PRR, Inc, 87-106, 2003.
17. Vassilopoulou-Sellin R, Gagel RF, Chan KW. Thyroid Cancer. In: M.D. Anderson Cancer Care Series. 5. Ed(s) Raney B, 2003.
18. Vassilopoulou-Sellin R. Neuroendocrine function. In: Cancer in the Nervous System, 2nd. Ed(s) V Levin. Churchill-Livingstone, 536-42, 2002.
19. McCarty T, Vassilopoulou-Sellin R, Lustig R. Thyroid & Parathyroid Cancer. In: Cancer Management: A Multidisciplinary Approach, 6th. Ed(s) Pazdur R, Coia L, Wagman L. PRR, Inc: Huntington, New York, 79-96, 2002.
20. Brower ST, Williams WL Jr, Vassilopoulou-Sellin R, Lusting R. Endocrine malignancies. In: Cancer Management: A Multidisciplinary Approach, 1st. Ed(s) Pazdur R, Coia L, Wagman L. PRR, Inc: Huntington, New York, 468-89, 1996.
21. Allison A, Vassilopoulou-Sellin R. Endocrine tumors. In: Medical Oncology, a Comprehensive Review, 2nd. Ed(s) Pazdur R. PRR, Inc: Huntington, New York, 483-92, 1996.
22. Sellin JH, Vassilopoulou-Sellin R, Lester R. Disorders that cause hypothyroidism: The gastrointestinal tract and liver. In: Werner's The Thyroid. A Fundamental and Clinical Text, 5th. Ed(s) Ingbar SH and Braverman LE. J.B.Lippincott Co: Philadelphia, 1156-62, 1986.
23. Sellin JH, Vassilopoulou-Sellin R, Lester R. Disorders that cause thyrotoxicosis: The gastrointestinal tract and liver. In: Werner's The Thyroid. A Fundamental and Clinical Text, 5th. Ed(s) Ingbar SH and Braverman LE. J. B. Lippincott Co: Philadelphia, 871-8, 1986.

Books (edited and written)

1. Habra MA, Vassilopoulou-Sellin R. Atlas of Endocrine Neoplasia, 2006.

Manuals, Teaching Aids, Other Teaching Publications

1. Habra M, Vassilopoulou-Sellin R. Atlas of Endocrine Neoplasia, CD format, 2004.
2. Organization of Dr. Naguib Samaan's slide collection into a publishable book, Atlas format. 2004.

Last updated: 2/13/2013